Share on LinkedInShare on LinkedIn

ARTICLE · 14 SEPTEMBER 2007

Federal Circuit Makes D.C. Swallow its Own Medicine

The U.S. Court of Appeals for the Federal Circuit affirmed a district court’s ruling that the District of Columbia’s Prescription Drug Excessive Pricing Act of 2005 (the Act) is preempted by federal patent laws and facially unconstitutional as invalidated by the Commerce Clause of the United States Constitution.

United StatesIntellectual Property

The U.S. Court of Appeals for the Federal Circuit affirmed a district court’s ruling that the District of Columbia’s Prescription Drug Excessive Pricing Act of 2005 (the Act) is preempted by federal patent laws and facially unconstitutional as invalidated by the Commerce Clause of the United States Constitution. Biotechnology Indus. Org. v. District of Columbia, Case No. 06-1593 (Fed. Cir., Aug. 1, 2007) (Gajarsa, J.).

According to the Act, "[a] prima facie case of excessive pricing shall be established where the wholesale price of a patented prescription drug in the District is over 30% than the comparable price in any high income country in which the product is protected by patents or other exclusive marketing rights." Once a prima facie case of "excessive pricing" is shown, the burden shifts to the defendant to prove that the price is not excessive.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from